Qiagen received FDA clearance for a gram-positive bacterial and fungal bloodstream infection test that runs on the QiaStat-Dx platform, extending the company’s BCID assay menu in the U.S. The cleared assay adds to existing respiratory, GI, and CNS panels available on QiaStat-Dx, enabling faster pathogen identification for bloodstream infections that can escalate rapidly in clinical settings. Qiagen framed the approval as part of an ongoing expansion strategy for its cartridge-based molecular diagnostics used in clinical microbiology workflows. —